

# The largest reported series of ibrutinib-treated CLL patients in clinical practice in the US: focus on rates and reasons for discontinuation



Retrospective analysis

621

Chronic lymphocytic leukemia (CLL) patients



Ibrutinib either commercially (n=546, 88%) or on clinical trials



80

Ibrutinib in front line



536

Ibrutinib in relapse

Mean age

58 years

61 years

p=0.01



Median time of follow-up: 17 months

Median progression-free survival

35 months

Overall survival

not reached

Ibrutinib discontinuation

42% patients

## Reasons for ibrutinib discontinuation

- Toxicity

63.1% (n=12)

50% commercial use  
77.7% clinical trial

50.2% (n=116)

52.5% commercial use  
39.7% clinical trial

- Progression disease

15.8%

20.9%

- RT DLBCL

5.3%

5.0%